17 Results for "

antidiabetic efficacy

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "antidiabetic efficacy" in MCE Product Catalog:

12
12 Publications Verification
Cat. No.: HY-15655
CAS No.: 196808-24-9
Purity:  99.93%
Target:  

PPAR

GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-13070
CAS No.: 1030612-90-8
Purity:  99.04%
Research Areas:  

Metabolic Disease

MK-8245 is a potent, liver-targeted stearoyl-CoA desaturase (SCD) inhibitor, with IC50s of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with antidiabetic and antidyslipidemic efficacy .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-126144
CAS No.: 187325-53-7
Purity:  98.04%
Target:  

GSK-3

Research Areas:  

Metabolic Disease Cancer

GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC50 of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-13077
CAS No.: 1415559-41-9
Purity:  98.45%
Research Areas:  

Metabolic Disease

MK-8245 trifluoroacetate is a liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-123797
CAS No.: 666842-36-0
Purity:  98.84%
Target:  

SGLT

Research Areas:  

Metabolic Disease

KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy .
loading...
    loading...
Cat. No.: HY-14945
CAS No.: 442201-24-3
Purity:  99.81%
Synonyms: GSK189075
Target:  

SGLT

Research Areas:  

Metabolic Disease

Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
loading...
    loading...
Cat. No.: HY-147257
CAS No.: 1844874-26-5
Purity:  99.07%
Synonyms: HSK7653
Target:  

Dipeptidyl Peptidase

Research Areas:  

Metabolic Disease

Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .
loading...
    loading...
Cat. No.: HY-114853
CAS No.: 756813-87-3
Target:  

PPAR

Research Areas:  

Metabolic Disease

BVT.13 is an orally active and selective PPARγ agonist with a maximal efficacy similar to that of Rosiglitazone (HY-17386). In addition, BVT.13 exhibits antidiabetic activity in ob/ob mice .
loading...
    loading...
Cat. No.: HY-138007
CAS No.: 1414248-06-8
Target:  

ROR PPAR LXR

SR-1903 is an inverse agonist of RORγ and PPARγ (IC50 of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .
loading...
    loading...
Cat. No.: HY-126144A
CAS No.: 3367-88-2
Purity:  99.03%
Target:  

GSK-3

Research Areas:  

Metabolic Disease

(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM .
loading...
    loading...
Cat. No.: HY-110022
CAS No.: 1217466-21-1
GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential .
loading...
    loading...
Cat. No.: HY-162637
CAS No.: 3047448-30-3
Target:  

Glycosidase

Research Areas:  

Metabolic Disease

CTL26 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 2.81 µM. CTL26 shows anti-diabetic efficacy .
loading...
    loading...
Cat. No.: HY-14747
CAS No.: 625114-41-2
Synonyms: RO4389620
Target:  

Glucokinase

Research Areas:  

Metabolic Disease

Piragliatin (RO4389620) is an activator for glucokinase, which reduces endogenous glucose production, increases β-cell function and glucose utilization, and thus decreases the blood glucose levels. Piragliatin exhibits antidiabetic efficacy .
loading...
    loading...
Cat. No.: HY-19606
CAS No.: 132971-59-6
Synonyms: Antibiotic MI 43-37F11
Cytogenin (Antibiotic MI 43-37F11) is an orally active antineoplastic antibiotic. Cytogenin regulates the inflammatory cytokine, reduces the levels of iNOS, NO and IL-6 in mouse macrophages, and exhibits antidiabetic efficacy in mice. Cytogenin inhibits growth of Ehrlich ascites tumor in mouse model .
loading...
    loading...
Cat. No.: HY-170874
CAS No.: 2897652-01-4
Target:  

PPAR

Research Areas:  

Metabolic Disease

PPARγ modulator-2 (Compound (R)-2n) is the reversible modulator for PPARγ that inhibits PPARγ ligand-binding domain (LBD) with an IC50 of 41 nM. PPARγ modulator-2 reduces blood glucose, improves the glucose tolerance and insulin tolerance, and exhibits anti-diabetic efficacy in db/db mouse models .
loading...
    loading...
Cat. No.: HY-162639
CAS No.: 1624628-01-8
α-Glucosidase-IN-68 (Compound 2) is an inhibitor for α-Glucosidase, AChE, and BChE, with IC50 of 0.251, 0.774 and 0.793 μM, respectively. α-Glucosidase-IN-68 exhibits antioxidant efficacy, with IC50 of 0.69 μM and 0.02 μM, in DPPH and ABTS experiments. α-Glucosidase-IN-68 exhibits antidiabetic effect in Streptozotocin (HY-13753)-induced diabetic rat models .
loading...
    loading...
Cat. No.: HY-166548S
CAS No.: 1233515-93-9
Synonyms: GSK189075-d7
Remogliflozin etabonate-d7 (GSK189075-d7) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
loading...
    loading...
  • 1